Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03521687 · ClinicalTrials.gov registry record · Phase 4
Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT03521687 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 20 participants.
The verdict
NCT03521687, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single-center, open-label clinical study to study the efficacy of apremilast in the treatment of mild to moderate central centrifugal cicatricial alopecia. The investigators hypothesize that the anti-inflammatory properties of apremilast may play a role in the decreasing scalp inflammation in patients with CCCA and may prevent further hair loss and potentially induce hair regrowth in patients with mild to moderate disease.
Interventions
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2021-02-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03521687
The ClinicalTrials.gov registry entry for NCT03521687 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apremilast is the first listed.
NCT03521687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03521687 about?
NCT03521687 is a clinical study titled "Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)". This is a single-center, open-label clinical study to study the efficacy of apremilast in the treatment of mild to moderate central centrifugal cicatricial alopecia. The investigators hypothesize that the anti-inflammatory properties of apremilast may play a role in the decreasing scalp inflammation...
What is the current status of trial NCT03521687?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2018-11-15. Estimated completion is 2021-02-12.
What interventions are being tested in trial NCT03521687?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT03521687?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.